EDAP TMS S.A. (Vaulx-en-Velin, France) announced the continuation of its U.S. phase II/III clinical trial of treatment using high-intensity focused ultrasound (HIFU) in men with prostate cancer. An additional two patients have been treated at Virginia Urology Center, Richmond, where Anthony Sliwinski, MD, and David Miller, MD, are leading the study.
EDAP TMS S.A. (Vaulx-en-Velin, France) announced the continuation of its U.S. phase II/III clinical trial of treatment using high-intensity focused ultrasound (HIFU) in men with prostate cancer. An additional two patients have been treated at Virginia Urology Center, Richmond, where Anthony Sliwinski, MD, and David Miller, MD, are leading the study.
"The EDAP Ablatherm-HIFU equipment is very easy to use. The ultrasound technology and safety features of the equipment make my part effortless," Dr. Sliwinski said. "Thus far, we have treated four men using this technology. Our first two patients had a very positive experience and an immediate reduction in their PSA results. Both men have been enthusiastic spokesmen for this procedure.
"Our most recent treatments lasted shortly over 2 hours, and immediate results seem excellent. This procedure appears to be a wonderful alternative to the many current treatment options for prostate cancer."
The study is currently enrolling men over age 50 years diagnosed with clinical stage T1a, T1b, T1c, or T2a localized prostate cancer.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.